Cytosorbents (CTSO) Debt to Equity (2016 - 2026)

Cytosorbents has reported Debt to Equity for 10 years, with the latest figure at $7.73 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity rose 692.44% year-over-year to $7.73; the trailing twelve-month figure through Mar 2026 stood at $7.73 (up 692.44% YoY), and the FY2025 full-year result was $2.82, up 124.07% from the prior year.
• Debt to Equity for Q1 2026 stood at $7.73, up from $2.82 in the prior quarter.
• The five-year high for Debt to Equity was $7.73 in Q1 2026, with the low at $0.14 in Q4 2022.
• Historically, Debt to Equity has averaged $1.42 across 5 years, with a median of $0.98 in 2025.
• Annual changes were most pronounced in 2023 — Debt to Equity surged 51.95% — and 2026, when it jumped 692.44%.
• Cytosorbents' Debt to Equity stood at $0.14 in 2022, then jumped by 51.95% to $0.21 in 2023, then jumped by 486.72% to $1.26 in 2024, then surged by 124.07% to $2.82 in 2025, then surged by 173.77% to $7.73 in 2026.
• The last three Debt to Equity figures came in at $7.73 (Q1 2026), $2.82 (Q4 2025), and $1.61 (Q3 2025), per Business Quant data.